We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.75 | 2.86% | 27.00 | 26.50 | 27.50 | 27.25 | 26.00 | 26.00 | 417,286 | 08:26:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -3.19M | -0.0469 | -5.60 | 17.87M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/7/2022 22:10 | Aah Galapagos continues fibrosis pipeline build-out with Evotec deal By Nick Paul Taylor Feb 7, 2019 02:05pm fibrosisEuroBiotech ReportEvotecGalapago Share Galapagos Galapagos is paying an upfront fee and committing to milestones and royalties to secure global rights to the drug. (Galapagos) Galapagos has secured the global rights to a preclinical fibrotic disease program from Evotec. The small molecule will slot into the growing fibrosis pipeline Galapagos is building through internal R&D and deals. Belgium-based Galapagos indicated its interest in striking deals to bolster its fibrosis pipeline last month when it struck a deal to collaborate on a novel idiopathic pulmonary fibrosis (IPF) target with Fibrocor Therapeutics. Fibrocor worked with CRO Evotec to generate the data package that attracted the interest of Galapagos. For its latest deal, Galapagos has gone direct to Evotec, which discovers drugs as well as working on assets owned by other companies. Evotec’s in-house activities have yielded a small molecule fibrosis drug that Galapagos sees as a good fit for its pipeline. Read into it what you want. Points. Galapagos and sareum link up Belgium!! You know if you know Momelotinib...myelof Sierra oncology takeover by GSK 1st July 2022 evotec acquired GSK Verona site All a coincidence Nothing to see here | criticalthinker1 | |
05/7/2022 19:08 | Hi CriticallyWhatever.. No... Love, Gekko...xxx | gekko2023 | |
05/7/2022 19:05 | Hi. Critical whatever here. Serious question. Is there any link between Sareum, Galapagos and Transgene re solid tumors? I appreciate there are links to Galapagos with Sareum, but any with all three? Appreciate any constructive response. Many thanks in advance. | criticalthinker1 | |
05/7/2022 17:43 | Assume the position...get on all 4s...and await Froth2 making his dry entry you cretin...xxx | gekko2023 | |
05/7/2022 17:36 | I haven't had a look here in a while but I see it's still the same empty vessel making a lot of noise. Instead of being a BB for Sareum it's turned into someone's safe place to rant about what happens on the LSE BB. Sad really. | countbruga | |
05/7/2022 14:24 | Where has criticalwinker1 gone?! Hope he's messaging gsk twitter to let them know they now own 737...a compound so great that sierra left it on a shelf for years....xxxx Lh&k | gekko2023 | |
05/7/2022 13:23 | Have all the other posters here gone strangely quiet?! Wonder why lol...xxx | gekko2023 | |
05/7/2022 12:49 | All dump...no pump, here these days... | gekko2023 | |
05/7/2022 12:25 | All dump...no pump, here these days... | gekko2023 | |
05/7/2022 12:00 | Sareum...healing the world etc...x | gekko2023 | |
05/7/2022 09:22 | CriticalStinker1...t | gekko2023 | |
04/7/2022 23:40 | Critical Stinker1 you come across like someone with severe learning difficulties and/or on the spectrum of something...for the love of God, give up...xx | gekko2023 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions